Alpha-1 antitrypsin deficiency

Findings suggest patients with AATD with liver and/or lung disease face greater all-cause costs and healthcare resource utilization than those with AATD alone.

Using available literature, the review assesses our current understanding of AATD, emerging biomarkers, and the future of drug development.

Patients with AATD-associated lung disease on augmentation therapy participating in a health management program experienced negligible changes in self-perceived health status.

Patients with AATD had increased cardiovascular risk compared to non-AATD COPD and healthy controls, with results suggesting physiological tests may assess risk more accurately.

A Veterans Affairs study finds low alpha-1 antitrypsin phenotyping rates, indicating the need for improved healthcare provider education on AATD.